Get the Stockscreener App
1.04
1.89%
-0.02
Femasys Inc stock is traded at $1.04, with a volume of 76,831.
It is down -1.89% in the last 24 hours and down -18.11% over the past month.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics.
See More
Previous Close:
$1.06
Open:
$1.06
24h Volume:
76,831
Relative Volume:
0.45
Market Cap:
$23.75M
Revenue:
$950.10K
Net Income/Loss:
$-16.69M
P/E Ratio:
-1.0833
EPS:
-0.96
Net Cash Flow:
$-15.16M
1W Performance:
+6.45%
1M Performance:
-18.11%
6M Performance:
-18.75%
1Y Performance:
+0.97%
1-Day Range:
$1.03
$1.07
1-Week Range:
$0.96
$1.20
52-Week Range:
$0.734
$2.40
Femasys Inc Stock (FEMY) Company Profile
Name
Femasys Inc
Sector
Industry
Phone
770-500-3910
Address
3950 JOHNS CREEK COURT, SUWANEE
Compare FEMY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FEMY
Femasys Inc
|
1.04 | 23.75M | 950.10K | -16.69M | -15.16M | -0.96 |
|
ISRG
Intuitive Surgical Inc
|
538.55 | 192.83B | 7.87B | 2.24B | 586.00M | 4.25 |
|
BDX
Becton Dickinson Co
|
221.98 | 64.77B | 20.18B | 1.73B | 3.07B | 5.51 |
|
ALC
Alcon Inc
|
88.23 | 43.75B | 9.76B | 1.16B | 665.00M | 0.72 |
|
RMD
Resmed Inc
|
249.33 | 36.84B | 4.81B | 1.11B | 1.35B | 6.16 |
|
WST
West Pharmaceutical Services Inc
|
323.32 | 23.33B | 2.88B | 499.60M | 321.60M | 7.41 |
Femasys Inc Stock (FEMY) Latest News
The Latest Analyst Ratings For Femasys - Benzinga
Femasys Announces Peer-Reviewed Publication of Positive - GlobeNewswire
Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed® Infertility Treatment - Yahoo Canada Finance
Femasys price target lowered to $8 from $10 at Chardan - MSN
Femasys Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Femasys Inc. (FEMY) Quarterly 10-Q Report - Quartzy
Femasys Inc. (FEMY) Reports Q3 Loss, Tops Revenue Estimates - MSN
Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update - The Manila Times
Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides - The Bakersfield Californian
Femasys Sales Surge 127% as Boston IVF Partnership, FDA Clearance Fuel Growth | FEMY Stock News - StockTitan
Femasys to Exhibit at the Annual AAGL 2024 Global Conference - GlobeNewswire
FEMYFemasys Inc. Latest Stock News & Market Updates - StockTitan
Femasys Partners with Boston IVF to Expand Access to Novel Fertility Treatment - Femtech Insider
Femasys secures new patent for FemBloc birth control By Investing.com - Investing.com South Africa
Femasys issued U.S. patent covering FemBloc device - MSN
Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control - GlobeNewswire
Femasys secures new patent for FemBloc birth control - Investing.com
The 10 Best Booths from ASRM 2022 - Exhibitor Online
Femasys (NASDAQ:FEMY) Has Debt But No Earnings; Should You Worry? - Simply Wall St
Femasys Announces Partnership with Boston IVF, Prominent Network of Fertility Centers, to Offer FemaSeed - GlobeNewswire
Femasys Advances in Women’s Health Innovation - TipRanks
Femasys to Exhibit at ASRM 2024 and Participate in the Congress’ KEEPR Education Program - GlobeNewswire
Femasys to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit - The Manila Times
Femasys Receives Second Order from Spain Partners After - GlobeNewswire
Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments - StockTitan
Femasys announes infertility clinic customers from coast to coast - TipRanks
Femasys Announces Infertility Clinic Customers from Coast to Coast - GlobeNewswire
H.C. Wainwright maintains Buy rating on Femasys on secureing strategic Spain distribution - Investing.com India
Femasys Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga
Femasys secures distribution partnerships for commercialization of FemaSeed - TipRanks
Femasys Secures Strategic Distribution Partnerships for - GlobeNewswire
Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market - StockTitan
Femasys Stock Rises After FDA Clearance for FemChec Diagnostic Device - Yahoo Finance
Items Tagged with 'Femchec' - BioWorld Online
Femasys gains FDA clearance for new diagnostic tool FemChec - Investing.com India
Femasys Femchec receives FDA clearance - BioWorld Online
Femasys gains FDA clearance for new diagnostic tool FemChec By Investing.com - Investing.com UK
Femasys Inc. Receives U.S. FDA Clearance to Market - GlobeNewswire
Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check - StockTitan
Femasys to Exhibit at The Canadian Fertility and Andrology Society’s 70th Annual Meeting - GlobeNewswire
Femasys Shares Rise on CE Mark & Canada Approval for FemVue MINI - MSN
Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
Femasys Inc Stock (FEMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):